Transcatheter Mitral Valve Replacement

TMVR

Mitral Regurgitation (MR) is a serious cardiac problem Due to therapeutic risk most patient remain untreated

Mitral regurgitation (MR) is a condition in which the valve doesn't close properly. Blood leaks back into the left atrium, decreasing blood flow to the body and causing the left atrial pressure to rise. Transcatheter Mitral Valve Replacement (TMVR) is a cardiac intervention method in which the dysfunctional mitral valve is  replaced by a prosthetic valve, using a catheter-based approach. At TruLeaf Medical we are tackling this challenge in an original way.

heart from mayo2.JPG
Image of stock market screen

The Market

The transcatheter heart valve replacement market is facing substantial growth due to the incidences of mitral regurgitation worldwide.

With growing demand for transcatheter mitral valves, TruLeaf Medical's solution comes to answer a huge unmet need.

The Problem

The transition from very invasive procedures such as surgical heart valve replacement to less invasive procedures govern the interventional cardiology for a few decades now. Following the success of Transaortic valve replacement, a significant demand for transcatheter mitral valve replacement (TMVR) arises.  Many challenges are associated with TMVR but one problem stands out as the most fundamental one – anchoring the implant into place. The anchoring problem and the attempts to solve it are the subject of a long-lasting development effort.

Image by Volodymyr Hryshchenko
Image by Jukan Tateisi

The Challenges

Moving from open heart surgery to percutaneous procedures has posed new challenges, not seen before. A paradigm shift is required to solve the mitral problem, in which percutaneous approach is mandatory, and there is no room for trans-apical procedures